Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
US9221814B2 · kind B2 · utility
8Cited by
9References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2013 |
| Grant date | Dec 29, 2015 |
| Priority date | — |
| Expiry date | Jun 7, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.